Myelodysplastic Syndrome
News
Vidaza® Approved for High-risk MDS
(08/22/2008)
The US Food and Drug Administration (FDA) has approved Vidaza® (azacitadine) for the treatment of high-risk myelodysplastic syndromes. Vidaza is already approved for MDS that is categorized into all five French American British (FAB) subtypes. This information was recently released in a press release by Celgene Corporation.
Supportive Care and Hematologic Malignancies
(01/21/2008)
A Report from the 2007 American Society of Hematology (ASH) Meeting
Updates in the Management of Myelodysplastic Syndromes
(01/21/2008)
A Report from the 2007 American Society of Hematology (ASH) Meeting
Vidaza Improves Survival in High-risk Myelodysplastic Syndrome
(12/11/2007)
According to results recently presented at the 2007 annual meeting of the American Society of Hematology (ASH), the agent Vidaza® (azacitidine) improves survival among patients with high-risk myelodysplastic syndrome (MDS).
Myelodysplastic Syndrome: An Update from ASCO 2007
(10/12/2007)
At the 2007 American Society of Clinical Oncology (ASCO) meeting there were several interesting studies reported concerning supportive care issues in MDS, hypomethylating agents, growth factors, iron overload and prognostic factors.
More
Myelodysplastic Syndrome
Cancer News...